{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:04:14Z","timestamp":1790258654365,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lenalidomide is an immunomodulatory drug (IMiD) used to treat multiple myeloma (MM) patients. Lenalidomide destroys MM cells by inducing ubiquitination and the consequent degradation of Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3). High expression of IKZF1 and IKZF3 in MM results in less sensitivity to lenalidomide treatment and possible cytotoxic effect. Therefore, detecting the expression of IKZF1 and IKZF3 proteins is of utmost importance in the treatment of MM. Here, we report the fabrication of a novel label-free electrochemical immunosensor for the rapid detection and quantification of IKZF1 and IKZF3 using electrochemical impedance spectroscopy (EIS). Gold electrodes were used to fabricate the immunosensors by immobilizing IKZF1 and IKZF3 specific antibodies using cysteamine and PDITC crosslinkers. The immunosensors were able to detect IKZF1 and IKZF3 protein levels with respective low detection limits of 0.68 and 0.97\u2009pg\/ml (11.8 and 16.7 fM). Furthermore, the immunosensors\u2019 successful application in human serum and their high selectivity and sensitivity enables their possible application in other biofluids as simple point-of-care devices for monitoring multiple myeloma patients treated with lenalidomide, to prevent the drug\u2019s cytotoxicity and minimize its side effects.<\/jats:p>","DOI":"10.1038\/s41598-020-67241-w","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T10:03:59Z","timestamp":1593165839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide"],"prefix":"10.1038","volume":"10","author":[{"given":"Haya","family":"Abdulkarim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Zourob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Siaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"issue":"6","key":"67241_CR1","first-page":"373","volume":"95","author":"TC Michels","year":"2017","unstructured":"Michels, T. C. & Petersen, K. E. Multiple Myeloma: Diagnosis and Treatment. Am Fam Physician 95(6), 373\u2013383 (2017).","journal-title":"Am Fam Physician"},{"issue":"1","key":"67241_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5001\/omj.2013.02","volume":"28","author":"K Al-Farsi","year":"2013","unstructured":"Al-Farsi, K. Multiple myeloma: an update. Oman. Med. J. 28(1), 3\u201311 (2013).","journal-title":"Oman. Med. J."},{"issue":"10","key":"67241_CR3","doi-asserted-by":"publisher","first-page":"e1486356","DOI":"10.1080\/2162402X.2018.1486356","volume":"7","author":"MHS Awwad","year":"2018","unstructured":"Awwad, M. H. S. et al. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. Oncoimmunology 7(10), e1486356 (2018).","journal-title":"Oncoimmunology"},{"key":"67241_CR4","unstructured":"Goldman, D. A. Thalidomide use: past history and current implications for practice. Oncol Nurs Forum 28, (3), 471-7; quiz 478-9 (2001)."},{"issue":"21","key":"67241_CR5","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","volume":"126","author":"EC Fink","year":"2015","unstructured":"Fink, E. C. & Ebert, B. L. The novel mechanism of lenalidomide activity. Blood 126(21), 2366\u20139 (2015).","journal-title":"Blood"},{"issue":"Suppl 1","key":"67241_CR6","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.critrevonc.2013.05.013","volume":"88","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos, M. A., Terpos, E. & Niesvizky, R. How lenalidomide is changing the treatment of patients with multiple myeloma. Crit Rev Oncol Hematol 88(Suppl 1), S23\u201335 (2013).","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"67241_CR7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/leu.2016.384","volume":"31","author":"J Kr\u00f6nke","year":"2017","unstructured":"Kr\u00f6nke, J. et al. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). Leukemia 31(6), 1363\u20131367 (2017).","journal-title":"Leukemia"},{"issue":"6168","key":"67241_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343(6168), 301\u20135 (2014).","journal-title":"Science"},{"issue":"6168","key":"67241_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343(6168), 305\u20139 (2014).","journal-title":"Science"},{"issue":"4","key":"67241_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","volume":"124","author":"YX Zhu","year":"2014","unstructured":"Zhu, Y. X. et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 124(4), 536\u201345 (2014).","journal-title":"Blood"},{"issue":"5","key":"67241_CR11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3324\/haematol.2017.181628","volume":"103","author":"I Misiewicz-Krzeminska","year":"2018","unstructured":"Misiewicz-Krzeminska, I. et al. A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. Haematologica 103(5), 880\u2013889 (2018).","journal-title":"Haematologica"},{"key":"67241_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bios.2018.05.048","volume":"117","author":"S Eissa","year":"2018","unstructured":"Eissa, S. et al. Carbon nanofiber-based multiplexed immunosensor for the detection of survival motor neuron 1, cystic fibrosis transmembrane conductance regulator and Duchenne Muscular Dystrophy proteins. Biosens Bioelectron 117, 84\u201390 (2018).","journal-title":"Biosens Bioelectron"},{"issue":"1","key":"67241_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bios.2012.07.049","volume":"39","author":"R Elshafey","year":"2013","unstructured":"Elshafey, R., Tlili, C., Abulrob, A., Tavares, A. C. & Zourob, M. Label-free impedimetric immunosensor for ultrasensitive detection of cancer marker Murine double minute 2 in brain tissue. Biosens Bioelectron 39(1), 220\u20135 (2013).","journal-title":"Biosens Bioelectron"},{"key":"67241_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bios.2015.01.055","volume":"69","author":"S Eissa","year":"2015","unstructured":"Eissa, S., Siaj, M. & Zourob, M. Aptamer-based competitive electrochemical biosensor for brevetoxin-2. Biosens Bioelectron 69, 148\u201354 (2015).","journal-title":"Biosens Bioelectron"},{"key":"67241_CR15","doi-asserted-by":"crossref","unstructured":"Eissa, S. et al. Development of Impedimetric Immunosensors for the Diagnosis of DOCK8 and STAT3 Related Hyper-Immunoglobulin E Syndrome. Electroanalysis 30, 2018.","DOI":"10.1002\/elan.201800228"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67241-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67241-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67241-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:15:51Z","timestamp":1670328951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67241-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["67241"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-67241-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"28 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10424"}}